English 
Español
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Related Articles
-
UDIBI
Published: april 2nd, 2020 Development and Evaluation of a Set of Spike and Receptor Binding Domain‐Based Enzyme‐Linked Immunosorbent Assays...
-
UDIBI
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región....
-
UDIBI
November 8, 22 Altered neutrophil-to-lymphocyte ratio in sepsis secondary to canine parvoviral enteritis treated with and without an immunomodulator...
-
UDIBI
October 6, 2021 Increased survival in puppies affected by Canine Parvovirus type II using an immunomodulator as a therapeutic...
-
UDIBI
Published: September, 2019 A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer...
-
UDIBI
Published: August 28, 2022 Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies More information
-
-
UDIBI
Published: may 16, 2019 Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract Transferon®) More information
